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Abstract Acute phase protein expression is regulated by a 
variety of cytokines such as IL-1, IL-6, IL-11, tumour necrosis 
factor a, interferon-y, oncostatin-M, leukemia inhibitory factor, 
ciliary neurotrophic factor and cardiotrophin-1. Presently, IL-6 
is regarded as the most potent mediator of acute phase protein 
(APP) synthesis. It was shown that IL-6 and IL-6-type cytokines 
activate the so-called JAK/STAT pathway and finally regulate 
APP expression in liver cells. Since HGF/SF is also capable of 
regulating APP expression, we asked whether it might also 
signal via the JAK/STAT pathway. Here we show that 
incubation of human hepatocytes as well as hepatoma cells 
(HepG2) with HGF/SF results in activation of the transcription 
factor STAT3. This STAT3 activation after HGF/SF did not 
occur before 5-7 h and was maintained up to 28 h. These 
observations are in contrast to the rapid and transient activation 
of ST ATI and STAT3 mediated by IL-6. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Higher organisms respond in a complex reaction to a vari-
ety of injuries such as bacterial, viral or parasitic infections, 
mechanical or thermal trauma, ischaemic necrosis or neoplas-
tic growth [1-3]. This so-called acute phase response consists 
of a local and a systemic reaction. The latter comprises endo-
crine and metabolic alterations, leucocytosis, increased hor-
mone release, activation of blood clotting and the complement 
system as well as a marked change in a group of plasma 
proteins which have been designated as acute phase proteins 
(reviewed in [4,5]). Acute phase proteins have been shown to 
be synthesized mainly by hepatocytes and secreted into the 
circulation. It is a well-known observation that APPs are dif-
*Corresponding author. Institut für Biochemie am Klinikum Aachen, 
Pauwelsstraße 30, D-52057 Aachen, Germany. 
Fax: (49) (241) 88 88428. E-mail: heinrich@rwth-aachen.de 
^F.S. and E.S. contributed equally to this work. 
Abbreviations: ACT, o¡i-antichymotrypsin; APP, acute phase protein; 
EMS A, electrophoretic mobility shift assay; HGF/SF, hepatocyte 
growth factor/scatter factor; IL, interleukin; JAK, janus kinase; 
STAT, signal transducer and activator of transcription 
ferently regulated in different species [5]. Cytokines such as 
IL-1, TNFa, IL-6 and the more recently described IL-11, 
oncostatin M, leukemia inhibitory factor, ciliary neurotrophic 
factor and cardiotrophin-1 regulate the expression of APPs in 
liver cells [6]. Thus far, IL-6 seems to be the major mediator 
of APP expression in hepatocytes [7,8]. 
IL-6 and IL-6-type cytokines are known to exert their ac-
tions via surface receptors composed of specific low affinity 
receptor a-chains and the common signal transducer gpl30 
[9,10]. Previous results from our laboratory and others have 
shown that IL-6 mediated APP regulation occurs through the 
JAK/STAT signalling pathway [11,12]. Binding of IL-6 to its 
receptor induces dimerization of gpl30 [13], activation of the 
gpl30-associated protein tyrosine kinases JAK1, JAK2 and 
TYK2 [11,12] and phosphorylation of gpl30 at tyrosine resi-
dues. Previously, we demonstrated that IL-6 triggers the rapid 
activation and tyrosine phosphorylation of a latent transcrip-
tion factor, acute phase response factor (APRF), which plays 
an important role in the induction of multiple APPs [14]. 
APRF turned out to be a member of the STAT family, 
namely STAT3a [15-17]. 
Recent work has shown hepatocyte growth factor/scatter 
factor as being capable of regulating APP synthesis in human 
[18] and rat [19] primary hepatocyte cultures although - com-
pared to IL-6 - the effects are weaker, and in some cases 
divergent. 
In the light of these data, we addressed the question of 
whether the regulation of HGF/SF-mediated APP synthesis 
occurs via the same transcription factor activation as in the 
case of IL-6. Here we show that HGF/SF regulates the ex-
pression of the APP ai -antichymotrypsin and activation of 
STAT3 in human hepatoma cells (HepG2) and in human 
hepatocytes in primary culture. The time course of STAT3 
activation by HGF/SF, however, differs markedly from that 
observed for IL-6 and its related cytokines. 
2. Materials and methods 
2.1. Reagents 
Oligonucleotides were purchased from MWG Biotech (Ebersberg, 
Germany), polyclonal antibodies to human ACT were from Dako-
patts (Hamburg, Germany). Polyclonal antibodies raised against a 
C-terminal fragment of STAT 3a were kindly supplied by Dr. Werner 
Müller-Esterl (Mainz, Germany); DMEM/F12 mixture and MEM 
plus supplements leucine, arginine, glucose and inositol, Ham F-12 
and Leibovitz L-15 culture media were from Gibco (Eggenstein, Ger-
many), fetal calf serum from Seromed (Berlin, Germany). Recombi-
nant human IL-6 was prepared as described in [20]. Its specific activity 
was 1 X 106 B-cell stimulatory factor-2 units/mg protein. Recombinant 
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Fig. 1. Stimulation of ACT synthesis by HGF/SF in HepG2 cells. 1.2x10s HepG2 cells per cm2 were incubated without (lower row) or with 
10 ng/ml of HGF/SF (upper row) for the times indicated. 12 h before the end of the experiment, cells were labeled with 3.75 MBq/ml of 
TRAN35S-LABEL in methionine/cysteine-free medium. ACT was immunoprecipitated from the conditioned medium with a specific antiserum 
and subjected to SDS-PAGE and autoradiography. Experiments were performed in triplicate. 
human HGF/SF was prepared in the baculovirus expression system. 
Its specific activity was 3.3 XlO6 units/mg of protein [21]. 
2.2. Cell cultures 
HepG2-cells (ATCC HB 8065) were grown in DMEM/F12 medium 
at 5% CO2 in a water-saturated atmosphere. Cell culture medium was 
supplemented with 10% fetal calf serum, streptomycin (100 mg/1) and 
penicillin (60 mg/1). 
Human hepatocytes were isolated from liver biopsies obtained in 
the course of a cholecystectomy after informed consent approved by 
the Ethics Committee of the hospital and cultured as described earlier 
[22]. 
2.3. Protein labelling and immunoprecipitation of ACT 
After seeding into a 96-well plate, HepG2 cells were initially grown 
in DMEM/F12 medium supplemented with 10% fetal calf serum for 
24 h, then cultured in serum-free medium and stimulated with 10 ng/ 
ml of recombinant human HGF/SF for different times. For subse-
quent protein labelling, cells were shifted to MEM plus 0.75 MBq 
per well of TRAN35S-LABEL (ICN) for 12 h. 180 ul of the 35S-
labelled cell culture supernatant were added to 96-well ELISA plates 
coated with 2.5 |ig ACT antibody per well, followed by incubation at 
37°C for 3 h. Plates were rinsed and bound proteins solubilized in 
SDS-PAGE loading buffer [23]. Proteins were separated by SDS-
PAGE [23] on a 10% gel, the gels fixed in 40% methanol, 10% acetic 
acid and 50% water for 30 min, dried and autoradiographed. For 
quantification of radioactive protein, gels were analysed with the Im-
age-Quant system (Molecular Dynamics). 
2.4. Nuclear extract preparation and electrophoretic mobility shift 
assay (EMSA) 
Nuclear extracts of HepG2 cells and primary human hepatocytes 
were prepared as described [24]. Protein concentrations were meas-
ured by the Bio Rad protein assay. EMSAs were performed as de-
scribed previously [25]. We used a double-stranded 32P-labelled probe: 
a mutated SIE oligonucleotide of the c-fos promoter (m67 SIE: 5'-
GAT CCG GGA GGG ATT TAC GGG GAA ATG CTG-3') [26]. 
Protein-DNA complexes were separated on a 4.5%> polyacrylamide gel 
containing 7.5% glycerol in 0.25 TBE at 20 V/cm for 4 h. Gels were 
fixed in 10%> methanol, 10% acetic acid and 80%o water for 30 min, 
dried and autoradiographed. For supershift assays, nuclear extracts 
were pre-incubated with 2 (xl of STAT3a antiserum for 15 min on ice 
and then used for EMSA. 
3. Results 
Previous studies have shown that IL-6 is a potent inducer of 
the acute phase protein ai-antichymotrypsin in hepatocytes 
and hepatoma cells [18,27]. Interestingly, H G F / S F has also 
been described as being a regulator of A C T expression in liver 
Fig. 2. Time dependence of STAT activation after incubation of HepG2 cells with HGF/SF. All HepG2 cells were cultivated for a period of 28 
h. Before the end of the experiment, cells were stimulated without or with either 10 ng/ml of HGF/SF or 100 pg/ml of IL-6 for the times indi-
cated. Nuclear extracts were prepared and analysed by EMSAs using an m67SIE probe specific for STAT1/STAT3 as previously described [25]. 
The panel on the right shows a supershift experiment with an antiserum specific for STAT3a (Müller-Esterl, Schaper, Küster, Heinrich, unpub-
lished work). Nuclear extracts were prepared from HepG2 cells stimulated with 10 ng/ml of HGF/SF for 15 h. 
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Fig. 3. Dose dependence of STAT3 activation by HGF/SF in HepG2 cells. HepG2 cells were incubated with increasing amounts of HGF/SF 
for 15 h. As described in the legend to Fig. 2, nuclear extracts were prepared and EMS As performed. 
cells [18]. Fig. 1 shows the effect of HGF/SF on the synthesis 
of ACT in the human hepatoma cells HepG2. A marked in-
crease (3-5-fold) between 36 and 48 h after addition of HGF/ 
SF was observed. The high rate of ACT synthesis remained 
unchanged up to 60 h (Fig. 1) and even up to 72 h (not 
shown) after HGF/SF administration. 
Since IL-6-induced expression of ACT, a typical class II 
APP, involves the activation of the transcription factors 
STAT1 and STAT3 [11,25,28], we investigated whether 
HGF/SF-mediated ACT expression also correlates with the 
activation of ST ATI and/or STAT3. When a STAT1 «-specif-
ic DNA probe was used to test nuclear extracts of HGF/SF-
treated HepG2 cells in an EMSA, we found activation of 
STAT3 beginning at 7 h after addition of the growth factor 
(Fig. 2). As shown by the supershift with a STAT3a-specific 
antiserum (right panel of Fig. 2) the gel shift band seen after 
HGF/SF treatment is completely shifted to lower mobility 
proving that it indeed represents STAT3cc. 
When HepG2 cells were stimulated with HGF/SF at in-
creasing concentrations for 15 h, a STAT3 activation was 
detected between 3 and 20 ng/ml HGF/SF, concentrations 
> 20 ng/ml resulted in a drastic reduction of signal intensity 
reaching control levels at a dose of 100 ng/ml (Fig. 3). 
It was of great interest to determine whether STAT3 acti-
vation is only a phenomenon occurring in hepatoma cells or 
whether it is also relevant in human hepatocytes. Fig. 4 clearly 
demonstrates the activation of STAT3 in human hepatocytes 
in primary culture upon stimulation with HGF/SF. The de-
layed STAT3 activation is similar to that observed in HepG2 
cells (Fig. 2). 
4. Discussion 
Hepatocyte growth factor and scatter factor are identical 
aß-heterodimeric glycoproteins mainly produced by mesen-
chymal cells that act predominantly on cells of epithelial ori-
gin which express the HGF/SF receptor. HGF/SF mediates all 
biological effects via its high-affinity cell-surface receptor c-
Met [29,30]. c-Met (190 kDa) is encoded by the c-met pro-
to-oncogene and composed of an extracellular a-chain (50 
kDa) and a membrane-spanning ß-chain (145 kDa). The in-
tracellular part of the ß-subunit contains a tyrosine kinase 
domain and several phosphorylation sites [29]. The Ras 
[31,32], phosphatidylinositol-3-kinase [33,34] and phospho-
lipase Cy [35] pathways are known to be activated after li-
gand-induced receptor phosphorylation. Up to now, there has 
been no evidence for a link between HGF/SF signalling and 
the JAK-STAT pathway. 
The diversity of HGF/SF-used signalling pathways might 
explain the multitude of its biological effects : HGF/SF stim-
Fig. 4. STAT3 activation after stimulation of human hepatocytes in primary culture with HGF/SF. Human hepatocytes in primary culture 
were incubated without or with either 100 pg/ml of IL-6 or 10 ng/ml of HGF/SF for the times indicated. STAT3 activation is demonstrated by 
EMSAs (see legend to Fig. 2). Supershift experiments using the STAT3a-specific antiserum are shown in the panel on the right: human hepato-
cytes were stimulated with 100 pg/ml of IL-6 for 30 min (lanes 1,2) or 10 ng/ml of HGF/SF for 7 h (lanes 3,4). Exposure times of the two 
autoradiographs differ. 
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ulates growth of various cell types, e.g. hepatocytes, kidney 
tubular epithelium, keratinocytes, endothelial cells and mela-
nocytes (reviewed in [29,30,36]). For hepatocytes, HGF/SF is 
the most potent mitogen, and it is believed to play an impor-
tant role in liver regeneration in vivo [36-38]. Moreover, HGF 
seems essential during embryonic development [39,40], partic-
ularly of the liver [41]. Angiogenesis and wound healing are 
also influenced by the action of HGF/SF [42,43]. Overexpres-
sion of HGF/SF and/or c-Met occurs in a wide variety of 
human tumors. The generation of an autocrine stimulatory 
loop is assumed to be crucial in tumor formation as well as 
in invasiveness and in vivo metastatic potential of tumor cells 
(reviewed in [40]). Other well-described features of the HGF/ 
SF are the induction of 'scattering' and increased motility as 
well as branching and other types of morphogenesis [44-49]. 
Although IL-6 is regarded as the major regulator of APP 
synthesis in liver [7,8], HGF/SF has recently also been found 
to be a regulator of APP expression [18,19]. 
Since IL-6 signalling involves the JAK/STAT pathway 
[11,12], we examined whether HGF/SF also uses components 
of this pathway. This could indeed be shown in the present 
work where we demonstrate HGF/SF-mediated STAT3 acti-
vation. In contrast to the rapid IL-6 signalling events [11,14], 
we observed a surprisingly delayed STAT3 activation after 
HGF/SF: In IL-6-stimulated HepG2 cells (Fig. 2) and hepa-
tocytes (Fig. 4), the tyrosine phosphorylation of STAT tran-
scription factors and their subsequent translocation to the 
nucleus - detectable by binding to an IL-6-responsive element 
- takes place between 5 and 30 min, leading to the transcrip-
tional activation of APP genes. In the case of HGF/SF, we 
did not observe STAT3 activation before 5-7 h after stimula-
tion with the growth factor. Further experiments should clar-
ify this phenomenon. The retarded STAT3 activation could be 
due to de novo synthesis of signalling molecules acting up-
stream of STAT3. 
A similar delay in STAT activation has been reported for 
the G-protein-coupled angiotensin II receptor system [50]. 
A further difference between the STAT3 activation after IL-
6 and HGF/SF was the long-lasting activation state of the 
transcription factor in the case of HGF/SF compared to the 
transiently activated transcription factor after stimulation 
with IL-6. Since STAT3 activation after IL-6 is due to tyro-
sine phosphorylation [11,12], it is possible that (a) tyrosine 
phosphatase(s) - acting as negative regulators of STAT activ-
ity - is (are) differently regulated by the two cytokines. 
Obviously there is need to identify the mechanisms respon-
sible for these kinetic features and the kinase(s) responsible 
for the HGF/SF-mediated tyrosine phosphorylation of 
STAT3. Recently, it has been demonstrated that the intrinsic 
tyrosine kinase of the epidermal growth factor receptor di-
rectly activates STAT3 [51]. Since c-Met is also a receptor 
tyrosine kinase, further work is required to show the possible 
role of this receptor kinase in STAT3 activation. 
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